Skip to main content
PLOS One logoLink to PLOS One
. 2023 Nov 8;18(11):e0287944. doi: 10.1371/journal.pone.0287944

Identification of natural antiviral drug candidates against Tilapia Lake Virus: Computational drug design approaches

Md Afsar Ahmed Sumon 1, Amer H Asseri 2, Mohammad Habibur Rahman Molla 3,*, Mohammed Othman Aljahdali 3, Md Rifat Hasan 4, M Aminur Rahman 5, Md Tawheed Hasan 6, Tofael Ahmed Sumon 7, Mohamed Hosny Gabr 1, Md Shafiqul Islam 8, Burhan Fakhurji 9, Mohammed Moulay 10, Earl Larson 11, Christopher L Brown 12,*
Editor: Abdulaziz Alouffi13
PMCID: PMC10631680  PMID: 37939069

Abstract

Tilapia Lake Virus (TiLV) is a disease that affects tilapia fish, causing a high rate of sudden death at any stage in their life cycle. Unfortunately, there are currently no effective antiviral drugs or vaccines to prevent or control the progression of this disease. Researchers have discovered that the CRM1 protein plays a critical function in the development and spreading of animal viruses. By inhibiting CRM1, the virus’s spread in commercial fish farms can be suppressed. With this in mind, this study intended to identify potential antiviral drugs from two different tropical mangrove plants from tropical regions: Heritiera fomes and Ceriops candolleana. To identify promising compounds that target the CRM1 protein, a computer-aided drug discovery approach is employed containing molecular docking, ADME (absorption, distribution, metabolism and excretion) analysis, toxicity assessment as well as molecular dynamics (MD) simulation. To estimate binding affinities of all phytochemicals, molecular docking is used and the top three candidate compounds with the highest docking scores were selected, which are CID107876 (-8.3 Kcal/mol), CID12795736 (-8.2 Kcal/mol), and CID12303662 (-7.9 Kcal/mol). We also evaluated the ADME and toxicity properties of these compounds. Finally, MD simulation was conducted to analyze the stability of the protein-ligand complex structures and confirm the suitability of these compounds. The computational study demonstrated that the phytochemicals found in H. fomes and C. candolleana could potentially serve as important inhibitors of TiLV, offering practical utility. However, further in vivo investigations are necessary to investigate and potentially confirm the effectiveness of these compounds as antiviral drugs against the virus TiLV.

Introduction

Tilapia is one of the most widely consumed, rapidly growing, and profitable families in worldwide aquaculture industries. Tilapia generally have desirable attributes including fast growth, tolerance of environmental changes, stress and disease resistance, ease of captive breeding, high protein content, and palatability [1]. However, aquatic viruses greatly impact the commercial aquaculture industry by causing sudden mortality, resulting in serious economic losses. Tilapia Lake Virus (TiLV) disease is one of the emerging and transboundary diseases of tilapia culture, causing up to 90% sudden mortality at any stage of culture [2]. Several tilapias, including the Nile (Oreochromis niloticus), Red (Oreochromis sp.), and hybrid tilapia derived from O. niloticus and O. aureus have been subject to infection with the TiLV [3]. With the increase in surveillance and diagnostic techniques in recent years, it is established that TiLV disease has spread across Asia, Africa, and North and South America [4]. TiLV is caused by a single-stranded (ss)-RNA virus, and its infection is characterized by various symptoms including lethargy, loss of appetite, respiratory distress, skin erosion, and brain lesions. Unfortunately, there are currently no effective therapeutic drugs available to control the spread of this virus [5].

The development of drugs that effectively target host proteins essential to the viral life cycle completion is a promising strategy for antiviral therapy development. CRM1 is a nuclear transporter protein that is understood to have a vital function in various virus families such as coronaviruses, retroviruses, flaviviruses, orthomyxoviruses, rhabdoviruses, paramyxoviruses, and herpesviruses [6]. CRM1 is among the most well-characterized Exportin-1 compounds (XPO1); CRM1-mediated export is used by a variety of viral species at various stages of their life cycles to ensure proper protein localization [7]. When CRM1, a protein responsible for cellular transport is blocked, the levels of Protein 4 in the cytoplasm and nuclei generally show increases. This pattern is reflective of the crucial role of CRM1 in exporting TiLV RNA from the nucleus. Inhibiting CRM1-mediated export has multiple effects on the virus. It leads to alterations in the expression of viral proteins, disrupts viral replication, and hinders the complete assembly of viral particles. As a result, the infectivity of the virus is reduced. Additionally, inhibiting CRM1-mediated export triggers a stronger antiviral immune response in the host, enhancing its ability to fight against the virus [8]. CRM1 binds to nuclear export sequences (NES)-cargoes in the nucleus via a cluster of leucine-rich or hydrophobic amino acids in the presence of RanGTP. The tri-complex (RanGTP) is hydrolyzed by RanGAP (a GTPase) resulting to RanGDP after translocation into the cytoplasm. After being released, CRM1 protein returns to the nucleus, and this cycle is repeated to take advantage of or regulate CRM1-mediated nuclear export [9]. A CRM1-targeting therapeutics drug has the potential to be precisely effective against TiLV, thereby inhibiting damage from the infection. Additionally, the compound PKF050-638 was first discovered as a suppressor of the HIV Rev protein; however, it also disrupts the activity of CRM1. The N-azolylacrylate scaffold was subsequently used by the SINE compounds, a group of small-molecule inhibitors that have a similar structure. This group includes KPT-185, KPT-276, KPT-335, KPT-330 (selinexor), KPT-8602 (eltanexor), and SL-801 (felezonexor). The SINE compounds have a unique affinity for Cys528 inside the cargo-binding groove of CRM1 [6].

It is imperative to discover viable phytochemicals and small bioactive molecules for drug development against infectious viral diseases in aquaculture through the investigation of novel compound interactions with the targeted viral protein [10]. Computational or in silico methods are assisting in making decisions and simulating virtually every aspect of drug discovery and development, which is a rapid and straightforward method for predicting liable compounds against certain drug targets [11]. Moreover, those compounds can be selected, documented and scored for their interactions based on molecular docking. The ADMET properties, which include absorption, distribution, metabolism, excretion, and toxicity, play a decisive role in determining the efficacy and safety of compounds in pharmacokinetics. Computer-aided methods can be employed for straightforward prediction of these properties. Additionally, MD simulation can be utilized to confirm potential drug candidate stability when interacting with the targeted protein [12].

Several marine and terrestrial plants have been discovered to contain bioactive compounds possessing antiviral drug properties [13]. Natural phytocompounds are increasingly being used as antimicrobial drugs in aquaculture instead of synthetic antibiotics [14]. Although it is challenging to develop novel drugs, advancing investigations for the discovery of bioactive compounds that target specific protein of infectious aquatic disease etiologies is urgently needed [15]. Previously, mangrove plants and medicinal plant garlic (Allium sativum) derived natural bioactive ligand was used against Nervous Necrosis Virus (NNV) capsid protein and in-silico study revealed the capacity of the ligand to inhibit this viral replication in Asian Seabass, Lates calcarifer [16]. Similarly, amphene is the best-screened phytochemical with the lowest binding energy with MX protein complex that can inhibit NNV infectivity in this species. Furthermore, a computational drug development approach revealed that phytocompounds, namely friedlein, phytosterols and 1-Triacontanol from Avicennia alba could bind to viral gag polyprotein and inhibit infectious Walleye Dermal Sarcoma Virus (WDSV) replication [15].

In recent decades, mangrove plants have been documented as a source of new chemical products with a rich assortment of natural bioactive properties. Mangrove plants, Heritiera fomes and Ceriops candolleana have a long history of use for medicinal and other purposes (making pickles, nuts, boats etc.) by people in coastal populations. Several studies have revealed that root, bark and leaves of both plants possess significant antioxidant, antinociceptive, antihyperglycemic, antimicrobial (such as antibacterial, antiviral and antifungal), and anticancer properties [17]. Compounds such as 10-undecenoic acid, methyl ester hexadecane dibutyl phthalate hexadecanoic acid, methyl ester undecylenic acid 9,12-octadecadienoic acid (Z,Z)-, methyl ester palmitic acid 2,5-anhydrogluconic acid aminopyrine procyanidins, phytosterols, 9-epiquinine, AC1L1UKB bis (acetic acid), tannins, cholesterol, delta 7-avenasterol, and squalene have been isolated from different parts of these two plants including root, bark and leaves, with impressive potential for a wide range of pharmaceutical products as replication inhibitors for various types of viruses, including TiLV [18].

To evaluate the potential of a new drug candidate against the TiLV virus, this research employed various readily available in-silico methodologies. These approaches included virtual screening, molecular docking, homology modeling, QM calculation, ADMET analysis, and MD simulation. The objective was to investigate the effectiveness of the drug candidate in targeting either CRM1 or XPO1 proteins associated with the TiLV virus.

Materials and methods

Phytochemical and protein preparation

The phytochemicals from the C. candolleana were sourced from the IMPPAT database, while those from H. fomes were obtained from published literature [19]. In total, 17 compounds from C. candolleana and H. fomes were collected and stored in a 2D (SDF) file format. To prepare ligands for further analysis, the phytochemicals were optimized and converted into pdbqt files. Similarly for the docking process, optimization and preparation of the proteins via AutoDock tool was conducted, and its corresponding file was saved in the pdbqt format.

Protein structure prediction through homology modeling

To obtain the TiLV structural CRM1 fasta sequence (NC_031978.2), the NCBI database (https://www.ncbi.nlm.nih.gov/gene/100703095, 30 April 2022) was exploited and submitted to the popular online web portal (https://zhanglab.dcmb.med.umich.edu/I‐TASSER/, on 30 April 2022), viz. Iterative Threading Assembly Refinement (I-TASSER) for confirmation or prediction of the 3D structure of the anticipated protein. The C-score, TM-score value, and root mean square deviation (RMSD) of the top five models of that structure were then provided by the I-TASSER [20].

Protein structure refinement and validation

The 3D protein structure was refined by uploading it online to GalaxyRefine (http://galaxy.seoklab.org/cgi‐bin/submit.cgi?type=REFINE, 7 May 2022), from which the data about the value of RMSD, energy score, and final structure quality were obtained. To select the refined structure, several parameters including RMSD, average distance among atoms and energy score were used. The refined structure was pictured using PyMol v2.3.4 software. For validation of the refined model, the Ramachandran plot scoring function was used [21].

Preparation of protein and ligand

Protein structures need to be refined and further validated before docking can take place. Thus, the selected 3D structure of CRM1 was generated using AutoDockTools (ADT). Nonpolar hydrogen atoms were combined, polar hydrogen atoms were introduced, and the Gasteiger charges of the protein were computed [22]. Additionally, it served as a cofactor and metal ion discarded from its protein. An extensive literature review and the database (https://cb.imsc.res.in/imppat/home) of Indian Medicinal Plant, Phytochemistry, and Therapeutics (IMPPAT) were used to identify the selected botanical compounds. Seventeen compounds were retrieved, among which 7 compounds were identified from C. candolleana and 10 compounds from H. fomes. To set and minimize energy for compounds selected from the database, The Universal Force Field (UFF) was used, as specifically designed for each ligand.

Identification of binding site and grid box generation

The refined protein structure of CRM1 was submitted to the CASTp 3.0 server (http://sts.bioe.uic.edu/, 10 May 2022) to predict the active site residues. Then, the server identified different active pockets, and the first of these was selected based on the pocket surface area (SA) and volume. The active pocket and corresponding AA residues were retrieved to visualize the binding pocket of the protein through the BIOVA Discovery Studio Visualizer Tool 16.1.0. The residues of the binding sites were then generated by BIOVA, used to select the grid box for molecular docking simulations [23].

Molecular docking simulation

PyRx software was used to run virtual screenings of selected compounds with analyses of the molecular docking process. The virtual screening software identified several hypothetical drugs to treat several diseases. In addition to the Lamarckian genetic algorithm (LGA) for scoring, AutoDock and AutoDock Vina for docking were provided. This study employed PyRx tools AutoDock Vina to perform docking interactions between molecules. For the analysis of complex binding poses, the BIOVA Discovery Studio Visualizer Tools 16.1.0.41 was used [24].

ADME analysis

During the preliminary drug development phase, an ADME assessment is required to determine a drug’s safety and efficacy in living systems. ADME properties depict pharmacokinetic behavior to predict the movement of drugs through and clearance out of the body. This study utilized the SwissADME (http://www.swissadme.ch, 11 May 2022) to interpret the response of selected drug candidates regarding pharmacodynamics [25].

Toxicity test

It is economically advantageous and vitally important to conduct toxicology tests during the drug development process in order to determine whether the compound has toxic properties, as well as for the assessment of dosage requirements. To assess the toxicity of chosen chemicals, in-silico computational approaches were utilized to evaluate their safety profiles. For early-stage toxicity evaluation, ProTox-II was used (http://tox.charite.de/protox_II, 11 May 2022), which simulated characteristics associated with the compounds’ acute toxicity, carcinogenicity, hepatotoxicity, mutagenicity, cytotoxicity, and immunotoxicity [26]. The investigators chose to use the Toxicity Estimation Software Tool (TEST) for the purpose of evaluating the toxicity of the chemical under investigation, eliminating the need for supplementary software. The use of quantitative structure-activity relationship (QSAR) methodologies has been employed to provide estimations for the chosen compounds. The pathways addressed by this website span a broad spectrum, including those associated with nuclear receptor signaling as well as those involved in the physiological response to stress [27].

Molecular dynamic (MD) simulation

The thermodynamic stability of the receptor-ligand system was evaluated using the Desmond v3.6 Program, which facilitated the automated simulation and free energy perturbation (FEP) calculations at different temperatures to predict the equation of state (EOS). Orthorhombic periodic boundary conditions were applied to simulate larger complex structures. To stabilize the system and achieve energetic neutralization, sodium ions were introduced and randomly placed [28]. MD simulations were conducted using the buffer box calculation method with a size of 10 Å and a specific box shape. Periodic boundary conditions and the NPT ensemble were employed during the simulations. Trajectories at 0 ns, 50 ns, and 100 ns were extracted for each ligand-CRM1 complex and then aligned. The retrieval and analysis of the resulting trajectory from the simulations was done using the Simulation Interaction Diagram (SID) in Schrödinger Release 2020–2.

MM-GBSA analysis

The free energy associated with the binding of chemicals and proteins was computed. The system under consideration is characterized by its complexity, and the score is determined by evaluating the free energy of binding based on the trajectory obtained from a molecular dynamics (MD) simulation. The MM-GBSA method was used to determine the binding free energy (Gbind) between certain compounds and the importin-11 protein. The Schrodinger Maestro software program was used for the computation of MM-GBSA.

Results

Protein 3D structure, refinement and validation

Among the models of CRM1 provided by I-TASSER, the best 3D protein structure was selected based on the lowest C-score (-0.01). Protein model-2 was picked following refinement, which had a 3D refined score of 37759.1, a GDTHA score of 0.9666, an RMSD value of 0.355, and no MolProbity issues. Prior to refinement, the Ramachandran plot analysis of CRM1 revealed that 97.629% of residues were in the favorable region, 2.062% were in the allowed region, and 0.309% were in the disallowed region. After refinement, the refined CRM1 model showed improved results, with 97.984% of residues in the favorable region, 2.016% in the allowed region, and 0.000% in the disallowed region (S1 Fig).

Identification of active site and receptor grid generation

The study first identified CRM1’s active side (AS) from CASTpi, then obtained its combined binding location (Fig 1). The protein binding site residue was identified through active pocket analysis (Fig 1). Four active pockets were selected from a total of 197 active pockets based on their surface area. The chosen active pockets and their corresponding amino acid residues are represented as balls in Fig 1. During the simulation procedure of molecular docking, the server-identified binding sites were used to build a receptor grid with grid box dimensions of X = 77.1430, Y = 81.9808, and Z = 93.4587 in angstroms (Å).

Fig 1. The surface area of the active pockets of CRM1 (selected four) was calculated using the CASTp server.

Fig 1

All the active sites i.e., AS1, AS2, AS3 & AS4 with their corresponding amino acids are depicted respectively in light blue, deep blue, yellow and red.

Molecular docking

After molecular docking of phytochemicals compounds, the binding affinity was determined to have varied between −3.2 and −8.7. The top 20% of the 17 phytochemicals with the highest binding affinity were selected. The top three compounds, specifically procyanidins (CID107876), delta7-Avenasterol (CID 12795736), and phytosterols (CID12303662), were chosen according to their docking scores respectively of −8.3, −8.2 and −7.9 kcal/mol. In addition, the commercially marketed drug Leptomycin B (docking score -6.6) was chosen and all four compounds were examined using various screening techniques. The three most favorably-ranked compounds scores are enumerated in Table 1, while docking scores are recorded in S1 Table for all the phytochemicals. Validation of those scores for the three selected compounds were confirmed by re-docking. The single-binding poses of three preselected phytochemicals were obtained and re-docked at the same binding site as before (S3 Table and S3 Fig). The RMSD values for the upper and lower ranges were determined, and it was found that the binding affinities of the phytochemicals remained similar to the earlier scores (S3 Table). The following four phytochemicals, CID107876, CID12795736, CID12303662 and CID6917907 with docking scores respectively of -8.3, -8.2–7.9 and -6.6 kcal/mol and zero (0) RMSD value were chosen. The root mean square deviations (RMSDs) of the expected postures from the observed binding modes for FlexX were calculated. The vast majority of the near solutions in this software have root mean square (RMS) deviations that are below 1.5 Å. The majority of active site postures may be classified within the range of 1.0 to 3.5 Root Mean Square (RMS) values. Nevertheless, it is evident that many active site solutions within the range of 0 to 2.0 rms were deemed to be near poses in the subjective analysis. This observation may be made by comparing the cumulative values for close assignments in S4 Table.

Table 1. The best three phytochemicals with their name, formula and CID.

PubChem ID Compounds Molecular Formula Molecular Weight Docking Score (kcal/mol)
107876 Procyanidin C30H26O13 594.5 -8.3
12795736 delta7-Avenasterol C29H48O 412.7 -8.2
12303662 Phytosterols C29H50O 414.7 -7.9
6917907 Leptomycin B C33H48O6 540.7 -6.6

List of Compounds, PubChem CID, Chemical Name, Molecular formula, molecular weight, and docking score of the seventeen selected compounds with the highest binding affinity are shown in S2 Table.

Protein‐ligand interaction analysis

Compounds that have the highest binding scores were chosen to see how they could interact with CRM1. Several hydrogen and hydrophobic bonds were reported to form between the compound CID107876 and the desired CRM1 (Fig 2). The hydrogen bonds were discovered to form at PRO427 and LYS590 position, while the hydrophobic bonds form at the location TYR454, VAL465, PRO1062, PRO1062, PRO1062, GLU459, ARG458, LYS455, and LYS455 position, as illustrated in Fig 3 and the bond types in Table 2.

Fig 2. The interaction between the chemical CID107876 and CRM1.

Fig 2

(A). The 3D interaction is shown on the left of the protein ligands, while the 2D interaction is shown on the right (B).

Fig 3. The interaction among chemical CID12795736 and CRM1.

Fig 3

(A). The 3D interaction is shown on the left of the protein ligands, while 2D interaction is shown on the right (B).

Table 2. Compilation of bonding interactions among three chosen phytochemicals and CRM1.

PubChem ID Residue Distance Category Type
CID 107876 PRO427 2.58 Hydrogen Bond (HB) Conv-H-Bond
LYS590 3 HB Conv-H-Bond
TYR454 5.6 Hydrophobic (HP) Pi-Pi- T-Shaped
VAL465 4.82 HP Pi-Alkyl
PRO1062 4.63 HP Carbon-H-Bond
PRO1062 3.57 HP Carbon-H-Bond
PRO1062 5.32 HP Carbon-H-Bond
GLU459 4.59 HP Pi-Cation
ARG458 3.87 HP Pi-Cation
LYS455 4.86 HP Pi-Cation
LYS455 5.13 HP Pi-Cation
CID 12795736 SER162 2.6 HB Conv-H-Bond
VAL120 4.64 HP Alkyl
ILE127 4.82 HP Alkyl
LYS124 5.09 HP Alkyl
VAL169 5.18 HP Alkyl
CID 12303662 VAL169 4.6 HP Alkyl
LYS124 5.07 HP Alkyl
ILE127 4.7 HP Alkyl
VAL120 4.78 HP Alkyl

The compound CID12795736 has formed several bonds in the VAL120, ILE127, LYS124, and VAL169 residual position, which were hydrophobic. Another two conventional hydrogen bonds were formed at the position of SER162 AA position as listed in Fig 3 and illustrated in Fig 4.

Fig 4. Interaction among chemical CID12303662 and CRM1.

Fig 4

(A). The 3D interaction is shown on the left of the protein ligands, while 2D interaction is shown on the right (B).

For compound CID12303662, also various hydrophobic bonds occurred with desired phytochemicals, with alkyl bonds in VAL169, LYS124, ILE127, and VAL120 residual positions as depicted in Fig 4 (and as listed in Table 2).

ADME analysis

The server SwissADME was used to evaluate the pharmacophore characteristics of the three chosen druglike compounds. The druglike compounds possess lipophilic characteristics which enable them to be dissolved in fats, oils, and other nonpolar solvents. Pharmacophore features demonstrated that the compound is effective and druggable, thus it may be employed in the research. The pharmacokinetic parameters discovered for the three chosen drugs are presented in Table 3. The ADME properties of the chosen three phytochemicals were found to be of high quality.

Table 3. The pharmacokinetics list comprises the ADME features of the three chosen drugs and various physicochemical features of these substances.

Properties Parameters CID 107876 CID 12795736 CID 12303662
  MW (g/mol) 594.52 g/mol 412.69 g/mol 414.71 g/mol
  Heavy atoms 43 30 30
  Arom. Heavy atoms 24 0 0
  Rotatable bonds 4 5 6
  H-bond acceptors 13 1 1
  H-bond donor 10 1 1
  Molar Refractivity 147.52 135.75 133.23
Lipophilicity Log Po/w 1.98 7.94 8.02
Water solubility Log S (ESOL) -4.9 -7.48 -7.9
Pharmacokinetics GI absorption Low Low Low
Drug likeness Lipinski, Violation No Yes Yes
Medi. Chemistry Synth. accessibility 5.64 6.03 6.3

Medi. Chemistry = Medicinal chemistry; Synth. Accessibility = Synthetic accessibility.

Toxicity prediction

The three compounds PubChem CID107876, CID12795736, and CID12303662 were selected previously through various screening processes. The compounds were subjected to analysis in ProTox-II server, which assessed their cytotoxicity, hepatotoxicity, oral toxicity, mutagenicity and carcinogenicity. However, Table 4 shows the phytochemicals that lack oral or organ toxicity effects. After toxicity testing, the results confirmed that the three selected compounds were either non-toxic or exhibited low toxicity levels. Moreover, Comparative Molecular Field Analysis (CoMFA) is a widely used three-dimensional quantitative structure-activity relationship (3D-QSAR) technique. The process of constructing a three-dimensional grid encompassing a molecule of interest and then evaluating the steric (shape) and electrostatic characteristics at each grid point is necessary.

Table 4. The drug-induced toxicity profile of selected phytochemicals.

PubChem ID Hepatotoxicity Carcinogenicity Immunotoxicity Mutagenicity Cytotoxicity
CID 107876 Inactive No Inactive Inactive Inactive
CID 12795736 Inactive No Light active Inactive Inactive
CID12303662 Inactive No Active Inactive Inactive

CoMFA result can provide valuable insights into the structure-activity relationship of the studied molecules. This information can aid in the design of novel compounds with the desired activity profiles by assisting researchers in gaining a better understanding of the factors that influence the biological activity of the molecules. The spatial arrangement of the four finest compounds results in steric effects. Three compounds, including CID107876, CID12303662, CID12795736 and their alignment were depicted in Fig 5. (S5 Table).

Fig 5. Construction of a three-dimensional grid encompassing a molecule of interest.

Fig 5

Subsequently, the steric (shape) and electrostatic characteristics are computed at each grid point using the Comparative Molecular Field Analysis (CoMFA) technique. This analysis is performed for a set consisting of the three chosen compounds.

MD simulation analysis

To investigate the constancy of the protein-ligand docking complexes, MD simulations were carried out. This simulation method offers valuable insights into the intermolecular interactions over time. A 100 ns simulation of MD was performed for intermolecular interactions among protein and ligand complex structure confirmation. The simulated trajectories were then utilized to assess parameters such as RMSD, Root Mean Square Fluctuation (RMSF), mapping of protein-ligand interactions, and analysis of ligand torsion. These analyses provided more depth in our understanding of the dynamic behavior and stability of the protein-ligand complexes.

RMSD

The RMSD values of three chemicals and the protein were analyzed to assess system equilibration. Specifically, the RMSD values of compounds CID107876, CID12795736, and CID12303662 were compared with the structure of CRM1, as shown in Fig 6, to identify any variations. The RMSD values for all compounds fell within the range of 1 Å to 2.5 Å, which was considered acceptable when contrasted to the CRM1 structure. Notably, the compound CID12795736 exhibited the highest stability between 65 ns to 100 ns simulation time. Additionally, compounds CID107876 and CID12303662 displayed initial fluctuations but gradually stabilized over time. The simulation was observed to converge between 40 ns and 100 ns for all compounds, with the RMSD values reaching a stable value (Fig 6). The marketable drug Leptomycin B was compared with other compounds, which fluctuated from 55 to 68 ns within the period. Consequently, the selected phytochemicals are deemed stable for the targeted protein. The root mean square deviations (RMSDs) of the sole ligand, expressed in units of nanoseconds (ns), are being considered in this analysis. The ligand-hiMGAM snapshots of three phytochemical substances (Phytosterols, Avenasterol, and Procyanidin) and a marketable medication (Leptomycin B) were overlaid at the start and end timeframes. The ligands and bound hiMGAM proteins are visually distinguished by the colours green and red, respectively, in relation to the extracted frames at 0 ns and 100 ns (S3 Fig).

Fig 6. RMSD values obtained from the Cα atoms of CRM1 (represented by blue curves).

Fig 6

Naturally occurring compounds were analyzed over a 100 ns simulation time. Specifically, the RMSD values for CID107876 are depicted as brown curves, CID12795736 as violet curves, CID6917907 as red curves and CID12303662 as green curves.

RMSF

To assess the displacement of specific atoms during the simulation, analyses of three RMSF complex structures were carried out. These values were further compared to the RMSF of the CRM1 structure, as shown in Fig 7, to observe atomic alterations. The highest peak of fluctuation was observed between residue points 184 and 396. Additionally, the entire complex structure exhibited fluctuation between residues 500 and 550, which was attributed to the location of N-terminal domain. Generally, the fluctuation of all the phytochemicals was found to be more optimal than the RMSF of CRM1. This indicates that the phytochemicals are capable of maintaining a steady interaction with no significant alteration of protein structure.

Fig 7. RMSF values extracted from the protein residue index Cα atoms of the complex structure.

Fig 7

Values shown include CID107876 (brown), CID12795736 (violet), CID12303662 (green), CID6917907 (red), and CRM1 (blue) regarding 100 ns of simulation time.

Protein-ligand contact mapping

Throughout the analysis of the 100ns MD simulation trajectory. The interaction between CRM1 and the three selected phytochemicals (CID107876, CID12795736, and CID12303662) were monitored. These interactions were categorized as hydrogen bonds, hydrophobic bonds, ionic bonds and water bridge bonds. The stacked bar graphs in Fig 8 show the summary of those interactions. All three of the selected compounds had a strong interaction with catalytic residues. The molecular dynamic simulation intervals of the screened compounds were found to contain a significant amount of intermolecular interaction. Active residues were discovered to interact with intermolecular and chosen ligands, and their density was determined for each of the three compounds studied. The active pocket of CRM1 was identified by the screening of natural chemicals and the study of MD trajectories. In real-life experiments, therefore, the screened natural compounds CID107876, CID12795736 and CID12303662 can be predicted to have a high degree of stability with the CRM1.

Fig 8. Stacked bars of the contact mapping of CRM1 with potential natural phytochemicals.

Fig 8

Illustrated here are (A) CID107876; (B) CID 12795736; and (C) CID 12303662 determined from simulations trajectory of 100 ns.

Ligands torsion analysis

The ligand torsions plot provides a summary of the conformational changes observed in each rotatable bond (RB) of the ligand during the entire simulation trajectory (0-100ns), as depicted in Fig 9. In the upper section, a two-dimensional representation of the ligand is shown, highlighting the RB (torsion) regions using different colors. Each RB torsion is accompanied by a dial plot and corresponding bar plots in the same color. The dial plots depict the changes in conformation of the torsions during the simulation. The center of the radial plot represents the beginning of the simulation, while the radial direction indicates the passage of time. The bar plots provide a summary of the dial plots, showing the probability density of the torsion at different time points. Furthermore, if information about the torsional potential is available, the plot also includes the potential energy of the RB by summing the potential energy of the relevant torsions. The values of the potential energy are displayed on the left Y-axis of the chart and are expressed in kcal/mol. Analyzing the histogram and the relationship between torsional potential and torsion values can offer insights into the strain experienced by the ligand in maintaining its conformational bond with the protein.

Fig 9. Ligand torsions plots.

Fig 9

These provide a summary of how each RB in the ligand underwent conformational changes throughout the entire simulation trajectory (from 0 to 100 ns).

MM-GBSA analysis

The estimation of the binding free energy between small molecules from mangrove plants and CRM1 has often been conducted by using molecular energies in conjunction with the commonly used Born and surface area continuum solvation methods. The subject matter was positioned within the spectrum of empirical scoring and rigorous alchemical perturbation methodologies (Fig 10). The binding free energy values obtained for the three compounds, namely CID: 107876, CID: 12303662, and CID: 12795736, in complex with CRM1, were determined to be -41.8499±5.08, -49.1706±12.41 and -35.0858±8.19 kcal/mol, respectively (S6 Table).

Fig 10. MM/GBSA calculation from the selected three compounds.

Fig 10

Binding free energy for each of the three compounds in association with CRM1 is given in kcal/mol and in Coulombs. Calculated No Strain binding values (NS) for each pair are also shown in both kcal/mol and Coulombs.

Solvent accessible surface area

The solvent-accessible surface area (SASA) has an impact on both the structure and function of biological macromolecules. The active sites of proteins are comprised of amino acid residues on their surfaces, which have the ability to bind ligands. This interaction allows for a better understanding of the hydrophilic or hydrophobic characteristics shown by molecules and protein-ligand complexes, resembling the behavior of solvents. Hence, Fig 11 exhibits the calculated solvent-accessible surface area (SASA) value of the protein while interacting with the chemical compounds (A) CID: 107876, (B) CID: 12303662, and (C) CID: 12795736. In the case of intricate systems, it was shown that the average solvent accessible surface area (SASA) value ranged from 200 to 300 A (Fig 11). This range indicates a substantial level of interaction between the amino acid residue and the molecule under investigation.

Fig 11. Solvent accessible surface area (SASA) of the protein–ligand complex.

Fig 11

These values were calculated from the compounds (A) CID: 107876, (B) CID: 12303662, and (C) CID: 12795736 until 100 ns simulation.

Discussion

Since the emergence of TiLV in 2014, eradication of the pathogen infectivity is the major concern of the world scientific community and virus researchers. So far, no anti-viral drug candidate has emerged that can effectively counteract these zoonotic pathogens. It has been found that TiLV’s protein 4 functions when CRM1 is inhibited, which plays a key role in the export of TiLV RNA [29]. Hence, this study was targeted to inhibit the CRM1 in TiLV through the identification and characterization of a novel and potentially effective bioactive antiviral drug compound. Computer-Aided Drug Design (CADD) is one of the most promising techniques for selecting novel compounds against a specific protein because it comprises a variety of highly advanced and nuanced characteristics and approaches [30]. CADD provides more affordable methods of designing, decreases recruitment costs, and reduces time in a new era of modern drug development. It has gained popularity and acceptance both in academic circles as well as among commercial pharmaceutical professionals. A process involving molecular docking, ADME-Tox prediction, and MD simulations are used to identify drug candidates that are predicted to possess the highest biological efficacy [31]. To understand disease mechanisms and facilitate drug design, it is crucial to identify disease-associated proteins and explore their interactions with potential ligands. By identifying compounds that can interact with and inhibit specific proteins essential for virus replication, it becomes possible to block viral infections and their progression. Through CADD, the specific target molecule can be identified based on its behavior and ligand’s binding mode. Additionally, molecular docking identifies the dominant modes of binding within a ligand, as well as protein and MD simulations revealing the mechanisms of protein-ligand interaction [32]. As a result, small-molecule candidates can be recognized as suitable drugs against a particular disease including TiLV infection.

In this study, we first predicted protein structure through Homology Modeling, then refined and validated by utilizing the popular online web portal (including, I-TESSER, GalaxyRefine). A homology-based structural model is widely used in identifying the effects of single nucleotide polymorphisms, as well as in drug design [33]. Homology models contain substantial information about the spatial arrangement of key residues in the protein to investigate the binding site and design/dock drugs that are suited for binding to the molecule. The most highly-ranked protein 3D structure (model 2) with the lowest c-score (‐0.01) generated from I-TESSER was used. To validate the refined model, the Ramachandran plot and z-score value scoring function was utilized. The model quality was increased after refining from the Galaxy Refine server, and the final refined model showed 97.984% in the most favored region in the Ramachandran plot and 0.0% in the disallowed region, indicating good model quality.

Seventeen natural phytochemical compounds were screened, and molecular docking simulations were performed to target the XPO1 to fight and block the replication of TiLV, and among those three most promising compounds were chosen in accord with their highest binding affinity scores for further validation. The compounds with higher docking scores were CID107876, CID12795736 and CID12303662 with binding scores of −8.3, 8.2 and −7.9 kcal/mol, respectively (see Fig 10 and S6 Table). Among these, CID 12795736 is estimated to have the strongest binding affinity with the target protein, but it also displayed the highest standard deviation, suggesting a higher degree of variability or uncertainty in the calculation. The strongest Coulombic interaction with the target protein was apparent for CID 107876, and this compound also displayed the lowest variability in calculated results.

Compounds derived from marine plants have shown antiviral and pharmacological properties against many illnesses. Marine plants and their components are of significant importance in the field of medication design research as well as in the preservation of animal and human life. Many herbal extracts derived from plants have been used to isolate individual molecules that exhibit potential as therapeutic candidates. These molecules are now being employed in many biochemical and biomedical fields [34]. The value obtained for the selected compounds was highly favorable and exhibited characteristic features with favorable indications of their potential as drug candidates. These compounds demonstrated drug-like qualities, as confirmed by their compliance with Lipinski’s Rule of Five (RO5). These selected three compounds have been evaluated and all compounds have shown a good value of the ADMET properties. Generally, the ADMET acts on the drug-related properties of pharmacokinetics (PK). Before developing a promising drug candidate, the PK parameters should be optimized since they need to pass standard clinical trials [31]. ADMET properties were traditionally predicted at the end of the drug discovery process, however, in-silico tools can predict them at an early stage. ADMET properties are responsible for 60% of drug molecules failing during the final drug development process. An early prediction of these properties would dramatically reduce the costs of drug research. Further toxicity evaluation has been conducted on the compound that has favorable ADME properties to evaluate the harmful effects on humans and animals. Toxicology testing is an important element of drug development, but it is costly and time-consuming to conduct on animals [35]. The alternatives to in silico approaches have been adopted before drug development as they do not need animal trials and are also time and cost-effective. Following toxicity testing, we confirmed that the three compounds chosen were non-toxic or low-toxic.

MD simulation has emerged as a valuable tool in computer-aided drug design (CADD) as it allows for the examination of the dynamic behavior of compounds within a specific macromolecular environment. In this study, MD simulation was employed to assess the stability of the selected drug candidates when interacting with the target macromolecule. Key parameters such as RMSD, RMSF, and ligand-protein interactions were analyzed to evaluate the complex system. The results indicated optimal RMSD and RMSF values, along with favorable protein-ligand contacts, for all three compounds [36]. Based on the findings, the three selected compounds have demonstrated favorable characteristics and stability when interacting with the target protein. Consequently, these phytochemicals show promise as potential candidates for further development as antiviral drugs targeting the TiLV.

Conclusions

The TiLV poses a substantial threat to the tilapia farming industry and to human food security, as it causes high mortality rates, and there is currently no effective antiviral medication available to combat the virus. This study aimed to identify potential natural antiviral drugs against the TiLV, with the goal of minimizing the frequency of virus infections. Three potential antiviral candidates, namely Procyanidins, delta7-Avenasterol, and Phytosterols, were selected through computer-aided drug design approaches such as homology modeling, molecular docking, ADMET, and MD simulation methods. These compounds hold promise in mitigating the economic losses in tilapia fisheries caused by the TiLV. This computational assessment will not only provide new information about the CRM1 insights into the TiLv but also will facilitate the treatment of fish virus in a significant and worthwhile manner. However, further in vivo and in vitro studies are recommended for the assessment of the effectiveness of these phytochemicals against TiLV in a practical way.

Supporting information

S1 Fig. Structural validation.

S1 Fig is included to show validation of the 3D structure of the CRM1 protein. (A) The Ramachandran plot statistics represent the most favorable, accepted, a disallowed region with a percentage of 97.984, 2.016, and 0.000%, respectively, and (B) the Z-score of refine gag protein −4.85.

(DOCX)

S2 Fig. Compound/protein interactions.

Illustrations of the three selected compounds and their interactions and active poses with protein after re-docking.

(DOCX)

S3 Fig. RMSDs of the sole ligands, phytosterols, avenasterol, procyanidin, and for comparison, leptomycin.

RMSDs are expressed in units of nanoseconds (ns) in this analysis. The ligand-hiMGAM snapshots of three phytochemical substances (Phytosterols, Avenasterol, and Procyanidin) and a marketable medication (Leptomycin B) were overlaid at the start and end timeframes. The ligands and bound hiMGAM proteins are visually distinguished by the colours green and red, respectively, in relation to the extracted frames at 0 ns and 100 ns.

(DOCX)

S1 Table. CRM1 active sites and corresponding binding sites.

Calculated locations of CRM1 binding and interactions with each of the three selected proteins.

(DOCX)

S2 Table. Docking scores of seventeen selected compounds.

These compounds were chosen for their relatively high binding affinities. The table illustrates the compounds, PubChem CID, their chemical names, molecular formulas, molecular weight, and docking scores of the seventeen selected compounds with highest binding affinities.

(DOCX)

S3 Table. RMSD values through re-docking.

This table illustrates the three compounds selected for their binding affinities and their respective RMSD values analyzed through the process of re-docking.

(DOCX)

S4 Table. RMS deviations.

This is a tabulation of RMS deviations as estimated using FlexX and SeeSAR software.

(DOCX)

S5 Table. Stearic and electrostatic effects.

The steric and electrostatic effects arising from the spatial arrangement of three most preferable compounds are tabulated & presented here.

(DOCX)

S6 Table. MM/GBSA values.

Calculated MM/GBSA (binding free energy) and No Strain (NS) binding values and their variance calculated for each of the selected three compounds.

(DOCX)

Acknowledgments

The authors gratefully acknowledge the understanding and encouragement provided by the Ministry of Education and King Abdulaziz University, DSR, Jeddah, Saudi Arabia.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This research was sponsored by Institutional Fund Projects under grant no. IFPIP: 874-130-1443, to author Amer H. Asseri. The authors gratefully acknowledge technical and financial support provided by the Ministry of Education and King Abdulaziz University, DSR, Jeddah, Saudi Arabia. These funders reviewed and approved the project concept but the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Abd El-Hack ME, El-Saadony MT, Nader MM, Salem HM, El-Tahan AM, Soliman SM, et al. Effect of environmental factors on growth performance of Nile tilapia (Oreochromis niloticus). Int J Biometeorol. 2022;66: 2183. doi: 10.1007/s00484-022-02347-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Nicholson P, Fathi MA, Fischer A, Mohan C, Schieck E, Mishra N, et al. Detection of Tilapia Lake Virus in Egyptian fish farms experiencing high mortalities in 2015. J Fish Dis. 2017;40: 1925–1928. doi: 10.1111/jfd.12650 [DOI] [PubMed] [Google Scholar]
  • 3.Saranya SR, Sudhakaran R. Report on prevalence of tilapia lake virus infection in tilapia fishes (Oreochromis niloticus). Biocatal Agric Biotechnol. 2020;27: 101665. doi: 10.1016/J.BCAB.2020.101665 [DOI] [Google Scholar]
  • 4.Mackey TK, Liang BA, Cuomo R, Hafen R, Brouwer KC, Lee DE. Emerging and reemerging neglected tropical diseases: a review of key characteristics, risk factors, and the policy and innovation environment. Clin Microbiol Rev. 2014;27: 949. doi: 10.1128/CMR.00045-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Eyngor M, Zamostiano R, Tsofack JEK, Berkowitz A, Bercovier H, Tinman S, et al. Identification of a novel RNA virus lethal to tilapia. J Clin Microbiol. 2014;52: 4137. doi: 10.1128/JCM.00827-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Mathew C, Ghildyal R. CRM1 inhibitors for antiviral therapy. Front Microbiol. 2017;8: 1171. doi: 10.3389/fmicb.2017.01171 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Sendino M, Omaetxebarria MJ, Rodríguez JA. Hitting a moving target: inhibition of the nuclear export receptor XPO1/CRM1 as a therapeutic approach in cancer. Cancer Drug Resist. 2018;1: 139–163. doi: 10.20517/CDR.2018.09 [DOI] [Google Scholar]
  • 8.Pickens JA, Tripp RA. Verdinexor targeting of CRM1 is a promising therapeutic approach against RSV and Influenza viruses. Viruses 2018, Vol 10, Page 48. 2018;10: 48. doi: 10.3390/v10010048 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Thakar K, Karaca S, Port SA, Urlaub H, Kehlenbach RH. Identification of CRM1-dependent nuclear export cargos using quantitative mass spectrometry. Mol Cell Proteomics. 2013;12: 664. doi: 10.1074/mcp.M112.024877 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Molla MHR, Aljahdali MO. Identification of phytochemical compounds to inhibit the matrix-like linker protein VP26 to block the assembles of white spot syndrome virus (WSSV) envelope and nucleocapsid protein of marine shrimp: In silico approach. J King Saud Univ—Sci. 2022;34: 102346. doi: 10.1016/J.JKSUS.2022.102346 [DOI] [Google Scholar]
  • 11.Opo FADM, Alkarim S, Alrefaei GI, Molla MHR, Alsubhi NH, Alzahrani F, et al. Pharmacophore-model-based virtual-screening approaches identified novel natural molecular candidates for treating human neuroblastoma. Curr Issues Mol Biol. 2022;44: 4838–4858. doi: 10.3390/cimb44100329 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hasan MR, Alsaiari AA, Fakhurji BZ, Molla MHR, Asseri AH, Sumon MAA, et al. Application of mathematical modeling and computational tools in the modern drug design and development process. Molecules. 2022;27: 4169. doi: 10.3390/molecules27134169 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Aljahdali MO, Habibur M, Molla R, Ahammad F. Immunoinformatics and computer-aided drug design as new approaches against emerging and re-emerging infectious diseases. Antivir Drugs [Working Title]. 2022. [cited 30 Aug 2022]. doi: 10.5772/INTECHOPEN.101367 [DOI] [Google Scholar]
  • 14.Islam MR, Awal MA, Khames A, Abourehab MAS, Samad A, Hassan WMI, et al. Computational identification of druggable bioactive compounds from Catharanthus roseus and Avicennia marina against colorectal cancer by targeting thymidylate synthase. Molecules. 2022;27. doi: 10.3390/MOLECULES27072089 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Aljahdali MO, Molla MHR, Ahammad F. Compounds identified from marine mangrove plant (Avicennia alba) as potential antiviral drug candidates against WDSV, an in-silico Approach. Mar Drugs 2021, Vol 19, Page 253. 2021;19: 253. doi: 10.3390/MD19050253 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Islam SI, Mou MJ, Sanjida S, Mahfuj S. Genetics of Aquatic Organisms 6(2), GA487 An In-silico approach for identifying phytochemical inhibitors against nervous necrosis virus (NNV) in Asian sea bass by targeting capsid protein. [cited 6 Dec 2022]. doi: 10.4194/GA487 [DOI]
  • 17.Samad A, Haque F, Nain Z, Alam R, Al Noman MA, Rahman Molla MH, et al. Computational assessment of MCM2 transcriptional expression and identification of the prognostic biomarker for human breast cancer. Heliyon. 2020;6. doi: 10.1016/j.heliyon.2020.e05087 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Islam SI, Mahfuj S, Alam MA, Ara Y, Sanjida S, Mou MJ. Immunoinformatic Approaches to identify immune epitopes and design an epitope-based subunit vaccine against emerging Tilapia Lake Virus (TiLV). Aquac J 2022; 2: 186–202. doi: 10.3390/AQUACJ2020010 [DOI] [Google Scholar]
  • 19.Mohanraj K, Karthikeyan BS, Vivek-Ananth RP, Chand RPB, Aparna SR, Mangalapandi P, et al. IMPPAT: A curated database of Indian medicinal plants, phytochemistry and therapeutics. BioRxiv. 2017; 206995. doi: 10.1101/206995 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Molla MHR, Aljahdali MO. Marine-derived sea urchin compounds as potential anti-cancer drug candidate against colorectal cancer: In silico and in vitro studies. Saudi J Biol Sci. 2023;30: 103748. doi: 10.1016/J.SJBS.2023.103748 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.AL-Refaei MA, Makki RM, Ali HM. Structure prediction of transferrin receptor protein 1 (TfR1) by homology modelling, docking, and molecular dynamics simulation studies. Heliyon. 2020;6. doi: 10.1016/J.Heliyon.2020.E03221 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc. 2016;11: 905. doi: 10.1038/nprot.2016.051 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Qasaymeh RM, Rotondo D, Oosthuizen CB, Lall N, Seidel V. Predictive binding affinity of plant-derived natural products towards the Protein Kinase G enzyme of Mycobacterium tuberculosis (MtPknG). Plants. 2019;8. doi: 10.3390/PLANTS8110477 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Cosconati S, Forli S, Perryman AL, Harris R, Goodsell DS, Olson AJ. Virtual screening with AutoDock: theory and practice. Expert Opin Drug Discov. 2010;5: 597. doi: 10.1517/17460441.2010.484460 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Reports 2017 71. 2017;7: 1–13. doi: 10.1038/srep42717 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Hemmerich J, Ecker GF. In silico toxicology: From structure–activity relationships towards deep learning and adverse outcome pathways. Wiley Interdiscip Rev Comput Mol Sci. 2020;10. doi: 10.1002/wcms.1475 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Habibur M, Molla R, Asseri AH, Islam MS. Integrated structure model-based virtual screening approaches identified anti-cancer agents against prostate cancer by targeting MAOB protein. Egypt J Med Hum Genet 2023 241. 2023;24: 1–20. doi: 10.1186/S43042-023-00431-Z [DOI] [Google Scholar]
  • 28.Salo-Ahen OMH, Alanko I, Bhadane R, Alexandre AM, Honorato RV, Hossain S, et al. Molecular dynamics simulations in drug discovery and pharmaceutical development. process 2021; 9: 71. doi: 10.3390/PR9010071 [DOI] [Google Scholar]
  • 29.De Clercq E. Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006;5: 1015. doi: 10.1038/nrd2175 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Tabassum H, Ahmad IZ. Molecular docking and dynamics simulation analysis of thymoquinone and thymol compounds from Nigella sativa L. that inhibits P38 protein: probable remedies for hepatocellular carcinoma. Med Chem. 2020;16: 350–357. doi: 10.2174/1573406415666190416165732 [DOI] [PubMed] [Google Scholar]
  • 31.Elekofehinti OO, Iwaloye O, Josiah SS, Lawal AO, Akinjiyan MO, Ariyo EO. Molecular docking studies, molecular dynamics and ADME/tox reveal therapeutic potentials of STOCK1N-69160 against papain-like protease of SARS-CoV-2. Mol Divers. 2021;25: 1761. doi: 10.1007/s11030-020-10151-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Mathew SM, Benslimane F, Althani AA, Yassine HM. Identification of potential natural inhibitors of the receptor-binding domain of the SARS-CoV-2 spike protein using a computational docking approach. Qatar Med J. 2021;2021. doi: 10.5339/qmj.2021.12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Quiroga R, Villarreal MA. Vinardo: A Scoring function based on autodock vina improves scoring, docking, and virtual screening. PLoS One. 2016;11: e0155183. doi: 10.1371/journal.pone.0155183 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Altamish M, Khan M, Baig MS, Pathak B, Rani V, Akhtar J, et al. Therapeutic potential of medicinal plants against dengue infection: a mechanistic viewpoint. ACS Omega. 2022;7: 24048–24065. doi: 10.1021/acsomega.2c00625 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Dong J, Wang NN, Yao ZJ, Zhang L, Cheng Y, Ouyang D, et al. ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. J Cheminform. 2018;10: 29. doi: 10.1186/s13321-018-0283-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Samad A, Huq MA, Rahman MS. Bioinformatics approaches identified dasatinib and bortezomib inhibit the activity of MCM7 protein as a potential treatment against human cancer. Sci Rep. 2022;12. doi: 10.1038/S41598-022-05621-0 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Abdulaziz Alouffi

14 Aug 2023

PONE-D-23-18810Identification of Natural Antiviral Drug Candidates Against Tilapia Lake Virus: Computational Drug Design ApproachesPLOS ONE

Dear Dr. Brown,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 28 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Abdulaziz Alouffi, PhD

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please note that PLOS ONE has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, all author-generated code must be made available without restrictions upon publication of the work. Please review our guidelines at https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse.

3. Thank you for stating the following financial disclosure:

“As specified in the acknowledgments, This research was funded by Institutional Fund Projects under grant no. (IFPIP: 1349-130-1443). The authors gratefully acknowledge technical and financial support provided by the Ministry of Education and King Abdulaziz University, DSR, Jeddah, Saudi Arabia.  “

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: N/A

Reviewer #3: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1. The English need improvement since there are some grammatical and syntax errors in the manuscript. For example,

• in line number 97, the words “a easy” may be as “an easy”;

• in line number 113, “in same” as “in the same”;

• in line number 137, “NCBI” as “the NCBI”;

• in line number 141, “anticipated” as “the anticipated”;

• in line number 145, “it in online” as “it online”;

• in line number 172, “had identified” as “identified”;

• in line number 173, “Lamarckian” as “the Lamarckian”;

• in line number 259, “2D” as “the 2D”;

• in line number 319, “has been” as “have been”;

• in line number 336, “compounds was” as “compounds were”;

• in line number 381, “simulations is” as “simulations are”;

• in line number 397, “lowest” as “the lowest”;

• in line number 404, “highest” as “the highest”.

The grammar mistakes which are not mentioned here are also to be checked and corrected properly.

2. There are some typing mistakes as well, and authors are advised to carefully proof-read the text. For example,

• in line number 118, the word “naturally” may be as “natural”;

• in line number 150, “refine” as “refined”;

• in line number 158, “plants” as “plant”;

• in line number 247, “Protein‐ Ligand” as “Protein‐Ligand”;

• Table 3, “Pharmakokinetics” as “Pharmacokinetics”;

• in line number 334, “shown” as “show”;

• in line number 340, “dynamic” as “dynamics”;

• in line number 398, “refine” as “refined”;

• in line number 421, “cost effective” as “cost-effective”.

The typos not mentioned here are also to be checked and corrected properly.

3. Check the abbreviations throughout the manuscript and introduce the abbreviation when the full word appears the first time in the abstract and the remaining for the text and then use only the abbreviation (For example, molecular dynamics (MD), CRM1, etc.,). Make a word abbreviated in the article that is repeated at least three times in the text, not all words to be abbreviated. The usage of abbreviations may be avoided in the keywords.

4. The author should uniformly follow some terms, for example, either “in silico” or “in- silico”.

5. The figure legends should be improved and a proper footnote should be given. All legends should have enough description for a reader to understand the figures without having to refer back to the main text of the manuscript. For example, the necessary abbreviations should be given.

6. The conclusion seems in general. All conclusions must be convincing statements on what was found to be novel, impact based on the strong support of the data/results/discussion. Moreover, the authors may also be included the limitation of the present findings for a better understanding of the manuscript.

Reviewer #2: Authors of the manuscript entitled “Identification of Natural Antiviral Drug Candidates Against Tilapia Lake Virus: Computational Drug Design Approaches” introduced computational approach for investigating the anti-viral potentiality for natural metabolites isolated from Heritiera fomes and Ceriops candolleana. Molecular docking analysis, in silico ADMET analysis, and molecular dynamics studies have highlighted the promising molecular reactivity and binding affinity of three identified hits. The manuscript is valuable in its field as it redeems publication following the address of these suggestions and comments:

1. The structure, nomenclature, and physiochemical properties of the identified 17 compounds should be presented even within the supplementary materials.

2. Section 3.2. Phytochemical and Protein Preparation, should be relocated to the materials and methods section rather than the in Results part.

3. Ramachandran plot should be presented at the supplementary materials.

4. The authors should adopt a positive control throughout the computational analysis to assess how the obtained results for the isolated natural metabolites would be of biological significance. Positive reference control could be a reported or market-approved inhibitor for the adopted CRM1 biotarget.

5. Validation of the docking protocol should be done through redocking protocol using the same docking algorism and parameters that are adopted for the investigated compounds has been recognized as a well-reported approach (See References; doi: 10.1021/jm0302997; doi: 10.1016/j.ejps.2020.105510; doi: 10.1016/j.bmcl.2019.02.031; doi: 10.1016/j.bioorg.2022.105770; doi: 10.3390/biology10050389). The ability of the molecular modelling simulation to replicate the ligand binding mode and residue-wise interaction patterns with low RMSD values (< 2.0 Å) between the native its redocked pose ensure the validity of the adopted protocol to provide binding pose of biological significance.

6. Authors provided comparative data regarding ligand binding modes through both highlighted polar hydrogen bonds and hydrophobic contacts. However, hydrogen binding should be presented within hydrogen bond distances as well as bond angles since hydrogen bond depend on both. Authors should mention the Hydrogen bond angles as well as their distances, since the strength of hydrogen bonding is based on both parameters in a way to ensure the adequacy of optimum hydrogen bonding.

7. Line 49, docking scores should be presented within their respective Kcal/mol units.

8. Through the RMSD and RMSF analysis, authors should illustrate trajectories for apo protein as well. This approach would better highlight the impact of compound’s binding on target through pinpointing flexible and immobile patterns for the protein ternary structures and amino acids in reference to the unliganded form. Difference RMSF (ΔRMSF = RMSFApo-Holo) could be adopted as well (please refer to doi: 10.1016/j.bmcl.2019.02.031 and doi: 10.1016/j.bmcl.2019.02.031).

9. Authors are advised to overlay of the initial, middle, and final frames (at 0 ns, 50 ns, and 100 ns, respectively) for each ligand-protein complex across the molecular dynamics simulations. This approach would provide great insights regarding the time-evolution orientation/conformation changes for both the protein and bounded ligands as well as the conserved and reformed ligand-amino acid bindings and close-range contacts.

10. Findings from the MM-GBSA free binding energy calculations as well as the constituting energy terms (VDW, electrostatic, solvation, SASA) should be represented in Figure or Table for better understanding the nature of ligand-target binding and the main driving energy terms for future structural improvements/optimization.

11. Authors should elaborate more on the discussion section through presenting comparative findings from reported literature studies that investigated other natural-isolated and/or even structural-related metabolites against the same target protein.

12. Finally, within the discussion sections, authors should highlight the takeaway messages that would be adopted in future lead optimization and development base on the docking, MD simulations, and ADMET studies. particularly, since two natural metabolites disobey Lipinski’s rule and cannot be considered as relevant clinical candidates. Prospective/recommended structure modifications to improve the ligand’s binding and interactions, as well as pharmacokinetics should be provided within the discussion and conclusion sections.

Reviewer #3: 1. Authors should discuss about the current clinical or preclinical or discovery status of CRM1 inhibitors as antiviral agents.

2. Is the selected target CRM1 validated clinically for viral inhibition??

3. Section 3.3- During the simulation procedure of molecular docking, the server-identified binding sites were used to build a receptor grid with grid box dimensions. Did the authors have generated grid box covering all the four pockets shown in Figure 1??

4. Section 3.4- top 20% of the 17 phytochemicals with the highest binding affinity were selected- How authors have come to this conclusion?? Is docking score alone sufficient to rank the compounds and that to on a predicted target protein and active pocket?? No comparison with standard or with binding interactions.

5. Have to perform MM-PBSA binding energy calculations to observe the energy variations and secondary structure analysis during the simulation time.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes: Manikanta Murahari

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Nov 8;18(11):e0287944. doi: 10.1371/journal.pone.0287944.r002

Author response to Decision Letter 0


7 Sep 2023

We have responded in detail to the reviewers responses and suggestions in our revised manuscript and in the response to reviewers document as uploaded.

Attachment

Submitted filename: Response to reviewers.docx

Decision Letter 1

Abdulaziz Alouffi

14 Sep 2023

PONE-D-23-18810R1Identification of Natural Antiviral Drug Candidates Against Tilapia Lake Virus: Computational Drug Design ApproachesPLOS ONE

Dear Dr. Brown,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 29 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Abdulaziz Alouffi, PhD

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1. There are some grammatical, alignments and typographical errors are noted in the manuscript and it should be thoroughly checked and corrected throughout the manuscript. For example,

• in line number 75, the words “to viral” may be as “to the viral”;

• in line number 79, “well characterized” as “well-characterized”;

• in line number 85, “disrupts” as “disrupt”;

• in line number 90, “tricomplex” as “tri-complex”;

• in line number 102, “investigation” as “the investigation”;

• in line number 103, “compounds” as “compound”;

• in line number 121, “best screened” as “best-screened”;

• in line number 140, “readily-available” as “readily available”;

• in line number 183, “BIOVA” as “the BIOVA”;

• in line number 208-209, and 331 “structure activity” as “structure-activity”;

• in line number 261, “compounds was” as “compounds were”;

• in line number 216, “single binding” as “single-binding”;

• in line number 273, “Tables” as “Table”;

• in line number 279, “Protein‐ Ligand” as “Protein‐Ligand”;

• “Pharmakokinetics” as “Pharmacokinetics”;

• in line number 319, “showed” as “shows”;

• in line number 387, “real life” as “real-life”;

• in line number 435, “protein– ligand” as “protein-ligand”;

• in line number 448, “era for” as “era of”;

• in line number 451, “simulations is” as “simulations are”;

• in line number 518, “computional” as “computational”.

2. This suggestion is not properly carried out The author should uniformly follow some terms either “in silico” or “in-silico”, for example, in line numbers 103 and 497 the authors have used “in silico” and in rest of the places “in-silico” has been used, it should be properly checked and corrected.

Reviewer #2: The authors addressed almost all suggestions and comments. However, two points should be addressed appropriately:

1. Adopting the protein's Cα as a reference for the analysed MD simulated trajectories is what meant by positive control for the in silico studies. owing to the lack of relevant experimental (wet lab) data, validation of the biological significance for the simulated ligands at docking and MD studies should be performed. Performing the same computational procedures for a literature reported or market-approved drug with experimental activity on the CRM1 biotarget and comparing them with those obtained for the isolated compounds would be relevant to extrapolate these computational data. Thus, it is advised to explore the docking and MD simulation of a literature reported or market-approved drug with CRM1 inhibition activity and compare these data wit those of the identified compounds.

2. The authors did not comprehend the concept of overlaying the 3D representation of the ligand-CRM1 complexes at initial, middle, and final frames. Trajectories at 0 ns, 50 ns, and 100 ns should be extracted for each ligand-CRM1 complex and then aligned. This would provide great insights regarding the time-evolution orientation/conformation changes for both the protein and bounded ligands as well as the conserved and reformed ligand-amino acid bindings and close-range contacts. authors are advised to refer to https://doi.org/10.3390/metabo13080942 for further guidance.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Prof. A. VIJAYA ANAND

Reviewer #2: Yes: Khaled M Darwish

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Nov 8;18(11):e0287944. doi: 10.1371/journal.pone.0287944.r004

Author response to Decision Letter 1


5 Oct 2023

All editorial recommendations have been accepted and impelemented in this revision, which is our second. That includes additional modeling work as suggested.

Attachment

Submitted filename: Review Rebuttal.docx

Decision Letter 2

Abdulaziz Alouffi

16 Oct 2023

Identification of Natural Antiviral Drug Candidates Against Tilapia Lake Virus: Computational Drug Design Approaches

PONE-D-23-18810R2

Dear Dr. Brown,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Abdulaziz Alouffi, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1. There are some grammatical, alignments and typographical errors are noted in the manuscript and it should be thoroughly checked and corrected throughout the manuscript. For example,

• in line number 113, the words “natural” may be as “from natural”;

• in line number 209, “methodologies has” as “methodologies have”;

• in line number 245, “active” as “an active”;

• in line number 283, “Protein‐ Ligand” as “Protein‐Ligand”;

• in line number 302, “also various” as “various”;

• in line number 362, “others” as “other”.

2. This suggestion is not carried out properly. The usage of abbreviations may be avoided in the keywords, for example TiLV.

3. This suggestion is not carried out properly. The author should uniformly follow some terms, for example, either “in silico (in line number 103, 502)” or “in- silico (in line number 118, 140, 202 etc.,)”.

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Prof. Dr. A. Vijaya Anand

Reviewer #2: Yes: Khaled M Darwish

**********

Acceptance letter

Abdulaziz Alouffi

23 Oct 2023

PONE-D-23-18810R2

Identification of Natural Antiviral Drug Candidates Against Tilapia Lake Virus: Computational Drug Design Approaches

Dear Dr. Brown:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Abdulaziz Alouffi

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Structural validation.

    S1 Fig is included to show validation of the 3D structure of the CRM1 protein. (A) The Ramachandran plot statistics represent the most favorable, accepted, a disallowed region with a percentage of 97.984, 2.016, and 0.000%, respectively, and (B) the Z-score of refine gag protein −4.85.

    (DOCX)

    S2 Fig. Compound/protein interactions.

    Illustrations of the three selected compounds and their interactions and active poses with protein after re-docking.

    (DOCX)

    S3 Fig. RMSDs of the sole ligands, phytosterols, avenasterol, procyanidin, and for comparison, leptomycin.

    RMSDs are expressed in units of nanoseconds (ns) in this analysis. The ligand-hiMGAM snapshots of three phytochemical substances (Phytosterols, Avenasterol, and Procyanidin) and a marketable medication (Leptomycin B) were overlaid at the start and end timeframes. The ligands and bound hiMGAM proteins are visually distinguished by the colours green and red, respectively, in relation to the extracted frames at 0 ns and 100 ns.

    (DOCX)

    S1 Table. CRM1 active sites and corresponding binding sites.

    Calculated locations of CRM1 binding and interactions with each of the three selected proteins.

    (DOCX)

    S2 Table. Docking scores of seventeen selected compounds.

    These compounds were chosen for their relatively high binding affinities. The table illustrates the compounds, PubChem CID, their chemical names, molecular formulas, molecular weight, and docking scores of the seventeen selected compounds with highest binding affinities.

    (DOCX)

    S3 Table. RMSD values through re-docking.

    This table illustrates the three compounds selected for their binding affinities and their respective RMSD values analyzed through the process of re-docking.

    (DOCX)

    S4 Table. RMS deviations.

    This is a tabulation of RMS deviations as estimated using FlexX and SeeSAR software.

    (DOCX)

    S5 Table. Stearic and electrostatic effects.

    The steric and electrostatic effects arising from the spatial arrangement of three most preferable compounds are tabulated & presented here.

    (DOCX)

    S6 Table. MM/GBSA values.

    Calculated MM/GBSA (binding free energy) and No Strain (NS) binding values and their variance calculated for each of the selected three compounds.

    (DOCX)

    Attachment

    Submitted filename: Response to reviewers.docx

    Attachment

    Submitted filename: Review Rebuttal.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES